- Home
- CLEU vs EVAX Comparison
CLEU vs EVAX Comparison
Compare CLEU & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLEU
- EVAX
- Stock Information
- Founded
- CLEU 2011
- EVAX 2008
- Country
- CLEU China
- EVAX Denmark
- Employees
- CLEU N/A
- EVAX N/A
- Industry
- CLEU Other Consumer Services
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLEU Real Estate
- EVAX Health Care
- Exchange
- CLEU Nasdaq
- EVAX Nasdaq
- Market Cap
- CLEU 20.0M
- EVAX 16.3M
- IPO Year
- CLEU 2020
- EVAX 2021
- Fundamental
- Price
- CLEU $2.05
- EVAX $1.65
- Analyst Decision
- CLEU
- EVAX Strong Buy
- Analyst Count
- CLEU 0
- EVAX 2
- Target Price
- CLEU N/A
- EVAX $10.00
- AVG Volume (30 Days)
- CLEU 58.7K
- EVAX 78.6K
- Earning Date
- CLEU 01-01-0001
- EVAX 05-27-2025
- Dividend Yield
- CLEU N/A
- EVAX N/A
- EPS Growth
- CLEU N/A
- EVAX N/A
- EPS
- CLEU N/A
- EVAX N/A
- Revenue
- CLEU $2,413,409.00
- EVAX $3,344,000.00
- Revenue This Year
- CLEU N/A
- EVAX $102.45
- Revenue Next Year
- CLEU N/A
- EVAX $100.30
- P/E Ratio
- CLEU N/A
- EVAX N/A
- Revenue Growth
- CLEU N/A
- EVAX 4480.82
- 52 Week Low
- CLEU $0.05
- EVAX $1.20
- 52 Week High
- CLEU $7.90
- EVAX $21.80
- Technical
- Relative Strength Index (RSI)
- CLEU 57.70
- EVAX 52.33
- Support Level
- CLEU $1.43
- EVAX $1.20
- Resistance Level
- CLEU $1.71
- EVAX $1.46
- Average True Range (ATR)
- CLEU 0.16
- EVAX 0.13
- MACD
- CLEU 0.03
- EVAX 0.06
- Stochastic Oscillator
- CLEU 100.00
- EVAX 90.00
About CLEU China Liberal Education Holdings Limited
China Liberal Education Holdings Ltd is an educational service provider operating in China. The company's operating segment includes Sino-foreign Jointly Managed Academic Programs, textbooks and course material sales, Overseas Study Consulting Services, Technological Consulting Services for Smart Campus Solutions and Tailored Job Readiness Training Services. Geographically, it derives revenue from China.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.